OR-2805
- Generic Name
- OR-2805
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
Phase 1
Recruiting
- Conditions
- CancerHead and Neck Squamous Cell CarcinomaMetastatic CancerLeiomyosarcomaTumor, SolidNon Small Cell Lung CancerMalignant NeoplasmAdvanced Solid TumorMelanomaLiposarcoma
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- OncoResponse, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05094804
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸NEXT Austin, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath